Treatments

Paxlovid tied to lower risk of problems for adults with kidney disease and COVID --study

Fri, 2025-01-03 16:28 — mike kraft

Paxlovid tied to lower risk of hospital stay, heart problems, death in adults with kidney disease and COVID The antiviral drug nirmatrelvir-ritonavir (Paxlovid) was linked to a lower risk of hospitalization within 30 days and major adverse cardiovascular events (MACEs) and death at 1 year in adults with COVID-19 and chronic kidney disease (CKD) or kidney failure, finds a study this week in Open Forum Infectious Diseases. CIDRAP

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Paxlovid tied to lower risk of problems for adults with kidney disease and COVID --study
Log in or register to post comments

Biden administration commits an additional $306 million toward battling bird flu and will distribute the funds before Trump takes office.

Fri, 2025-01-03 15:29 — mike kraft

The Biden administration, in a final push to shore up the nation’s pandemic preparedness before President-elect Donald J. Trump takes office, announced on Thursday that it would nearly double the amount of money it was committing to ward off a potential outbreak of bird flu in humans.

Federal health officials have been keeping a close eye on H5N1, a strain of avian influenza that is highly contagious and lethal to chickens, and has spread to cattle. The virus has not yet demonstrated that it can spread efficiently among people.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Five things we know and still don’t know about COVID, 5 years after it appeared

Fri, 2025-01-03 15:03 — mike kraft

5 things we know and still don't know about COVID, 5 years after it appeared Five years after the virus that causes COVID emerged in China it still holds some mysteries. The disease has killed an estimated 20 million people globally, according to the World Health Organization, and thousands are still dying every year. AP News

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Five things we know and still don’t know about COVID, 5 years after it appeared
Log in or register to post comments

Changes in Emergency Management of COVID-19 during pandemic--study

Fri, 2024-12-27 16:18 — mike kraft

Clinical and Operational Changes in ED Management of COVID-19 The following is a summary of “Correlates of improved outcomes in patients with COVID-19 treated in US emergency departments,” published in the December 2024 issue of Emergency Medicine by Slutske et al. Researchers conducted a retrospective study to evaluate the impact of therapeutic advances during the COVID-19 pandemic on clinically relevant metrics of emergency care. Physician's Weekly Admin Physician's Weekly

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Read more about Changes in Emergency Management of COVID-19 during pandemic--study
Log in or register to post comments

US FDA revokes authorization for four COVID antibody drugs

Tue, 2024-12-24 15:11 — mike kraft

US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based drugs, including those from Eli Lilly and Regeneron . Reuters Reuters

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about US FDA revokes authorization for four COVID antibody drugs
Log in or register to post comments

Paper that popularized unproven hydroxychloroquine COVID-19 treatment finally retracted

Wed, 2024-12-18 14:40 — mike kraft

https://www.science.org/content/article/infamous-paper-popularized-unproven-covid-19-treatment-finally-retracted

Infamous paper that popularized unproven COVID-19 treatment finally retracted

A 2020 paper that sparked widespread enthusiasm for hydroxychloroquine as a COVID-19 treatment was retracted today, following years of campaigning by scientists who alleged the research contained major scientific flaws and may have breached ethics regulations. The paper was pulled because of ethical concerns and methodological problems, according to a retraction notice.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Paper that popularized unproven hydroxychloroquine COVID-19 treatment finally retracted
Log in or register to post comments

XBB COVID vaccine estimated effective rate: 63% to 68% against more severe illness in kids

Fri, 2024-12-13 16:41 — mike kraft

XBB COVID vaccine estimated to be 63% to 68% effective against more severe illness in kids The adjusted effectiveness of the updated Pfizer/BioNTech COVID-19 XBB vaccine in the 2023-24 US respiratory virus season was 68% and 63% against hospitalization or emergency department (ED) or urgent-care visits among children aged 5 to 11 years and 12 to 17 years, respectively, with an overall effectiveness for both age-groups of 65%, a Kaiser Permanente Southern California (KPSC)-led research team estimates. CIDRAP

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about XBB COVID vaccine estimated effective rate: 63% to 68% against more severe illness in kids
Log in or register to post comments

Many long COVID patients face slim recovery odds as attention fades

Fri, 2024-11-15 15:41 — mike kraft

Many long COVID patients adjust to slim recovery odds as world moves on

...

The best window for recovery is in the first six months after getting COVID-19, with better odds for people whose initial illness was less severe, as well as those who are vaccinated, researchers in the United Kingdom and the United States found

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Many long COVID patients face slim recovery odds as attention fades
Log in or register to post comments

For older patients, Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief --two new studies

Tue, 2024-11-12 14:44 — mike kraft

Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find Overall, the risk of developing 28 out of 36 long-COVID symptoms lessened when vaccines were effective. CIDRAP

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Benefit seen only in older patients

Country / Region Tags:

General Topic Tags: